FAM
ALDR

Fred Alger Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Fred Alger Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-15,000
Closed -$177K – 563
2019
Q2 		$177K Hold
15,000
– – ﹤0.01% 402
2019
Q1 		$205K Buy
+15,000
New +$194K ﹤0.01% 394

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fred Alger Management's ALDR Position: Q3 2019 in Review

Fred Alger Management sold out of Alder Biopharmaceuticals (ALDR) in Q3 2019, closing a stake of 15,000 shares — an estimated $177K sold.

Fred Alger Management first reported a position in ALDR in Q1 2019 and held it in 2 quarters. The position peaked at $205K in Q1 2019. 143 funds tracked by Wall St. Rank hold ALDR as of Q3 2019.

  • Fred Alger Management reported no remaining Alder Biopharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Fred Alger Management sold 15,000 Alder Biopharmaceuticals shares in Q3 2019, an estimated $177K.
  • Fred Alger Management first reported a position in Alder Biopharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Fred Alger Management's Alder Biopharmaceuticals position peaked at $205K in Q1 2019.
  • 143 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2019.

Based on Fred Alger Management's 13F filing for Q3 2019, filed 14 Nov 2019.